Eagle Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Eagle Pharmaceuticals

10/05/2021 15:06

* Eagle Pharmaceuticals Inc  EGRX.OQ  reported quarterly
adjusted earnings of 24 cents​​ per share for the quarter ended
in March. The mean expectation of four analysts for the quarter
was for earnings of 65 cents per share.
* Revenue fell 10.4% to $41.25 million from a year ago​; 
analysts expected $45.41 million.
* Eagle Pharmaceuticals Inc's reported EPS for the quarter was a
loss of 3 cents​.
* The mean earnings estimate of analysts had risen by
about 66.7% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Eagle Pharmaceuticals Inc shares had fallen by 0.2% this
quarter and lost 10.6% so far this year.
* The company reported a quarterly loss of $421 thousand.
* Wall Street's median 12-month price target for Eagle
Pharmaceuticals Inc is $46.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 10 at 02:06 p.m. GMT.
​All figures in US Dollars.​